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Amilorides inhibit SARS-CoV-2 replication in vitro by
targeting RNA structures
Martina Zafferani1†, Christina Haddad2†, Le Luo2‡, Jesse Davila-Calderon2‡, Liang-Yuan Chiu2‡,
Christian Shema Mugisha3, Adeline G. Monaghan1, Andrew A. Kennedy4, Joseph D. Yesselman5,
Robert J. Gifford6, Andrew W. Tai4, Sebla B. Kutluay3, Mei-Ling Li7*, Gary Brewer7*,
Blanton S. Tolbert2*, Amanda E. Hargrove1*
The SARS-CoV-2 pandemic, and the likelihood of future coronavirus pandemics, emphasized the urgent need for
development of novel antivirals. Small-molecule chemical probes offer both to reveal aspects of virus replication and to serve as leads for antiviral therapeutic development. Here, we report on the identification of
amiloride-based small molecules that potently inhibit OC43 and SARS-CoV-2 replication through targeting of
conserved structured elements within the viral 5′-end. Nuclear magnetic resonance–based structural studies revealed specific amiloride interactions with stem loops containing bulge like structures and were predicted to be
strongly bound by the lead amilorides in retrospective docking studies. Amilorides represent the first antiviral
small molecules that target RNA structures within the 5′ untranslated regions and proximal region of the CoV
genomes. These molecules will serve as chemical probes to further understand CoV RNA biology and can pave the
way for the development of specific CoV RNA–targeted antivirals.
INTRODUCTION

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is
the etiological agent of the COVID-19 respiratory disease, the largest-
scale respiratory virus pandemic the world has witnessed since the
1918 Spanish flu and that has claimed more than 3.9 million lives
worldwide as of July 2021 (1–3). Coronaviruses (CoVs) generally
cause mild flu-like symptoms in humans but have caused two
smaller-scale pandemics in the last two decades: SARS-CoV (2003)
and MERS (2012) (4). Recent phylogenetic mapping traced all human
CoVs to animal origins (5). While the middle zoonotic carrier of the
virus between the animal of origin and humans seems to vary between CoVs, the chronological surfacing of human CoV pandemics
seems to follow a dangerous trend of increasing lethality of each
pandemic, thereby underscoring the need for a better understanding
and targeting of the current and future CoV etiologic agents.
After more than a year since the first cases of SARS-CoV-2 human
infection, this virus is expected to remain a global threat until vaccines are available and adopted worldwide. Furthermore, despite the
increase in number of approved vaccines, their implementation has
been hindered by the scarcity of doses available worldwide. On top of
the production rate, pharmaceutical companies are currently facing
challenges with the recently reported SARS-CoV-2 variants, against
which not all vaccines have proven sustained efficacy, highlighting
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the need for a synergistic antiviral-based approach (6). While recent
treatments have been approved for use within hospital settings, there
are no known U.S. Food and Drug Administration (FDA)–approved
cures for the infection (7).
Current candidates for treatment have limited approval for
emergency use in severe COVID-19 cases. Remdesivir, for example, is
an RNA-dependent RNA polymerase inhibitor (RdRp) initially developed during the Ebola outbreak and revisited at the start of the
pandemic (8). The compassionate use of the candidate antiviral across
many countries reported mixed results, with overall faster recovery
time from the virus but no difference in mortality rates (9). While
more randomized trials are needed for a final verdict on the efficacy of
remdesivir in critical patients, its stereospecific multistep synthetic
process highlights the need for new, scalable, and more efficacious
antivirals. Baricitinib has been recently approved for emergency use
for COVID-19 treatment in conjunction with remdesivir. Also known
as Olumiant, this small molecule was approved in 2018 as treatment
for moderate to severe rheumatoid arthritis (10). It is proposed that
the anti-inflammatory effects of the drug help in decreasing inflammatory cascades associated with COVID-19. While promising,
baricitinib has yet to receive approval as a stand-alone treatment
and, so far, has been shown to improve recovery time by 1 day when
compared with remdesivir-alone treatment (7).
The recent emergence of multiple coronavirus pandemics clearly
indicates that SARS-CoV-2 most likely will not be the last CoV
pandemic (4). The current limited tools and lack of cures underscore
the need for a new approach in developing antivirals that would
not only provide novel routes to combat the current pandemic but
also provide invaluable information on targetable structures that can
aid in the prevention of and fight against future CoV outbreaks.
Small molecules are uniquely poised to achieve this goal as their design and development provide both a better understanding of CoV
biology and identify druggable targets that could aid in the development of pan-coronavirus antivirals.
Several steps in the coronavirus replication cycle offer potential
therapeutic targets for viral inhibition (Fig. 1). CoVs are enveloped
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Fig. 1. SARS-CoV-2 replication cycle (56). The virus enters human cells via endocytosis by binding the ACE2 receptor and releasing its positive-sense RNA genome. The
virus exploits the host machinery to facilitate efficient viral replication, which ultimately leads to progression of infection (57).

positive-sense single-stranded RNA genomes of approximately
30 kilobases, making them the largest genomes of RNA viruses (4).
SARS-CoV-2 infects human cells by engagement of the ACE2 receptor by the viral spike (S) protein followed by membrane fusion at
the plasma membrane or endosomal membranes depending on the
availability of host cell proteases that cleave and prime S for entry.
Fusion results in the release of its genome and associated proteins in
the host cell cytosol. The genome is translated into two large polyproteins, 1a and 1b, which are then processed into individual proteins
by the viral protease. Synthesis of full-length negative-strand RNA
by products of 1a/1b creates a template to synthesize multiple positive
strand copies encapsidated by the viral nucleoprotein into virions (4).
The negative RNA strand also serves as a template for the synthesis of
shorter subgenomic RNAs that include the essential structural proteins and thus also constitute an attractive therapeutic target (11).
CoV antivirals to date have been developed to target viral proteins, including to prevent endocytosis, assembly of viral protein for
export, and condensation of viral genome for packaging (12). While
this protein-centric approach has been proven successful in a few
cases, the sequence and structural conservation of RNA structural
motifs pose an attractive complementary target for small-molecule
Zafferani et al., Sci. Adv. 7, eabl6096 (2021)
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antiviral development, a strategy that has shown promise against a
plethora of viruses (13, 14). Specifically, international efforts that
allowed for identification and tracking of SARS-CoV-2 variants
highlighted the large number of mutations accumulated in protein-
coding regions (15). At the same time, recent global cataloging of
mutations in the untranslated regions (UTRs) revealed a lower rate
of mutation, highlighting the potential of UTRs as drug targets (16).
Recently published data on genome-wide secondary structure of the
virus obtained by in vitro and in vivo SHAPE (selective 2′ hydroxyl
acylation analyzed by primer extension) and DMS (dimethyl sulfate)
probing of SARS-CoV-2–infected Vero E6 cells, as well as nuclear
magnetic resonance (NMR) characterization, recapitulates the
computationally predicted stem loops (SLs) at the 5′-region of the
genome (Fig. 2) as well other relevant frameshifting and replication-
related structures (17–20). Conserved elements at the 5′- and 3′-ends
have been identified across many members of the coronavirus family
and function as cis-acting elements regulating viral replication (21).
Specifically, studies on murine and bovine CoVs showed that phylogenetically conserved SLs in the 5′-UTR are capable of long-range
RNA-RNA and protein-RNA interactions responsible for optimal
viral replication (22, 23). More recently, studies aimed at uncovering
2 of 14
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Fig. 2. Secondary structure representation of the 5′-end (450 nt) of the SARS-CoV-2 RNA genome as determined by DMS chemical probing (18). Structure recreated
in VARNA.

the pathway that leads to viral protein synthesis via host cell
translation machinery revealed that the presence of the full-length
5′-UTR of SARS-CoV-2 leads to a fivefold increase in translation
of viral proteins. This preliminary data corroborate the importance
of the 5′-UTR region, and the structures within, for efficient viral
translation and provide context for the viral hijacking of the host
cell translational machinery (24).
Drug-like small molecules offer the ability to develop chemical
probes that reveal function and to design bioavailable clinical candidates for treatment. While RNA targeting has lagged behind protein
targeting, recent successes in both the laboratory and the clinic support its potential role. The first U.S. FDA–approved small molecule
targeting RNA other than the ribosome was approved for treatment
of spinal muscular atrophy in August of 2020 (25). Effective small-
molecule targeting in the laboratory has also been observed for a
plethora of disease-relevant RNAs, including viral RNAs. Specifically,
small molecules targeting structures within the 5′-UTR region have
shown antiviral activity for a number of positive-sense RNA viruses
such as HCV, FMDV, and EV71 (26–28). Recent studies have begun evaluating the potential of small molecules against the frameshifting elements of SARS-CoV-2 RNA in the coding region. These
recent reports include evaluation of known SARS-CoV pseudoknot
binders and development of a small-molecule binder to the attenuator
hairpin preceding the pseudoknot (29–32). Coupling of the latter
to the known ribonuclease-targeting chimera technology results in
recruitment of cellular ribonucleases leading to viral genomic
RNA degradation. In addition, a fragment-based screen against
structures in the 5′-UTR of SARS-CoV-2 was successful in identifying
potential ligands (31). While the antiviral activity of these molecules has
not been published, these preliminary results, combined with known
RNA-targeted antivirals for other positive-sense RNA viruses, stand
as proof of concept of the targetability of SARS-CoV-2 RNA motifs.
Zafferani et al., Sci. Adv. 7, eabl6096 (2021)
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Successful efforts to target viral 5′-UTR structures have often
leveraged the synthetic tuning of a known RNA binding scaffold
(26, 27, 33). We recently used this approach to develop RNA-targeted
antivirals based on dimethylamiloride (DMA) that target the internal
ribosomal entry site (IRES) region in the 5′-UTR of EV71. The
DMA scaffold had been previously reported to be poised for tuning
for specific RNA constructs via a facile three-step synthesis (27).
Further investigation and functionalization of the scaffold resulted
in a bioactive antiviral analog that formed a repressive ternary complex with IRES SL II RNA and the human AUF1 protein, ultimately
inhibiting translation and compromising viral replication. The
successes in DMA exploration highlight the scaffold’s potential for
tuning and broad applicability as an antiviral scaffold (27).
Here, we report DMA analogs that show promising antiviral
properties by reducing SARS-CoV-2 virus titer in a dose-dependent
manner in infected cells. In addition, dual-luciferase reporter assays
confirmed the antiviral activity of the small molecules to be dependent on the 5′-UTR and proximal region of the SARS-CoV-2 genome.
Investigation of possible conserved RNA binding sites of the lead
small molecules revealed putative bulge-like binding sites in SL1,
SL4, and SL5a, located in the 5′-UTR of the SARS-CoV-2 genome,
and in the adjacent SL6 located in ORF1a, supporting both the
targetability of 5′-region SLs. Together, these results establish
conserved CoV RNA structures as antiviral targets and reveal lead
molecules with promising antiviral properties.
RESULTS

Phylogenetic conservation of RNA structural elements
As the functional significance of the 5′-end SLs is still being elucidated, we examined sequence conservation in the 5′-end region across
the Betacoronavirus genus as a preliminary approach to assess the
3 of 14
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suitability of the known structures in this region as therapeutic targets.
Sequence conservation within the contexts of folded RNA domains
would imply selective pressures to exert biological function. We constructed a multiple sequence alignment spanning the 5′-UTR and the
adjacent region including representatives of all five betacoronavirus
subgenera (Fig. 3). Alignments disclosed the highest degree of conservation in the region encoding SL2 and SL3, both of which are
relatively short and contain stretches of 5 to 6 nucleotides (nt) that
are 100% conserved. By contrast, SL1 and SL4 to SL6 are less conserved, but notably, four of the five SLs that span the 5′-UTR contain
stretches of relatively highly conserved nucleotide sequence (i.e., 70
to 100% conservation across the genus). The position of these SL’s
within or adjacent to the 5′-UTR (which is relatively conserved in
length across all Betacoronaviruses) indicates that these conserved
regions are likely to represent homologous nucleotides and suggests
that they are, to some degree, functionally equivalent. Our findings
are in agreement with recent studies that reported sequence and
structural similarity among members of the Coronaviridae family,
suggesting that selective pressure plays a central role in conserving
RNA secondary structures essential for the viral life cycle.
DMAs inhibit human coronavirus OC43 virus replication
in a dose-dependent manner
We pursued targeting of the 5′-end SL structures with the DMA
scaffold, which has been previously reported as an RNA binding
scaffold that can be successfully optimized for selectivity for distinct
RNA elements (27). To quickly assess potential CoV antiviral activity,
human OC43 betacoronavirus was used because of its lower virulence and thus suitability for use in standard cell culture facilities (3).
Vero E6 cells were infected with human coronavirus OC43 at a
multiplicity of infection (MOI) = 1. After a 1-hour adsorption, a
panel of 23 DMAs at 50 or 100 M were added to the cells and incubated for 24 hours at 33°C. Virus titers were determined by plaque
formation on Vero E6 cells, and DMA-132, DMA-135, and DMA-155
(Fig. 4) reduced virus titer by ~1000-fold at 100 M concentration
(fig. S1). The results further suggest DMA-132, DMA-135, and
DMA-155 reduce virus titer in a dose-dependent manner (fig. S2).
The parent scaffold, DMA (DMA-1), demonstrated no activity and is
used as an inactive control moving forward.
Antiviral potency of DMAs against SARS-CoV-2
To determine the antiviral activity and potency of the lead small
molecules against SARS-CoV-2, we used a simplified quantitative
reverse transcription polymerase chain reaction (qRT-PCR) assay to
monitor SARS-CoV-2 viral RNA levels in supernatants of infected
Vero E6 cells (34). Similarly to remdesivir, DMA-135 and DMA-155
led to a dose-dependent 10- to 30-fold decrease in cell-free viral
RNA levels within 24 hours of infection with an approximate median
inhibitory concentration (IC50) of 10 and 16 M, respectively (fig. S4).
Antiviral activity of the three most active DMA leads (DMA-132,
DMA-135, and DMA-155) was confirmed using Vero E6 cells infected with wild-type SARS-CoV-2. Small-molecule treatment was
performed at 10 and 50 M, respectively. DMA-132 and DMA-135
showed dose-dependent reduction in virus titer compared to dimethyl
sulfoxide (DMSO), as measured by median tissue culture infectious
dose (TCID50) assay, without measurable effect on cellular viability
as measured by adenosine 5′-triphosphate (ATP) content (Fig. 5).
Virus titer and cellular content of ATP (CellGro) were normalized
to account for the expected variance of raw virus titer between
Zafferani et al., Sci. Adv. 7, eabl6096 (2021)
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experiments. Notably, all three DMA-132, DMA-135, and DMA-155
have improved antiviral activity when compared to DMA-01, the
parent scaffold, thereby corroborating the potential for synthetic
tunability of DMAs for SARS-CoV-2 targeting.
DMA-132, DMA-135, and DMA-155 were tested for longer-term
(96-hour) toxicity in Vero E6 cells. Small molecules do not substantially reduce cell viability <10 M, supporting a potential therapeutic
window, although more extensive cytotoxicity studies are warranted.
In particular, fig. S3 shows that the 50% cytotoxic concentration
CC50 of DMA-132 and DMA-135 in Vero E6 cells were >100 M.
CC50 of DMA-155 was about 90 M; so, only 10 M antiviral data
were collected.
Investigation of small-molecule activity against
CoV-2–luciferase reporter gene expression
To assess the effect of DMAs on reporter gene expression directed
by SARS-CoV-2 sequence elements, a reporter plasmid, pCoV-2–
5′UTR–FLuc–3′UTR was used as template for in vitro synthesis of
CoV-2–5′UTR–FLuc–3′UTR RNA (Fig. 6A). This plasmid contains
the 5′-end 805-nt segment from the virus genome and the 3′-UTR.
Thus, the 805-nt segment spans the genomic RNA 5′-UTR (SL1 to
SL5) and ORF1a encoding a portion of nsp1 (including SL6 to SL8)
fused in-frame with the firefly luciferase (FLuc) ORF. Plasmid pRL
was used as template for the synthesis of control Renilla luciferase
(RLuc) reporter RNA lacking SARS-Cov-2 sequences. The RNAs
were cotransfected, and various concentrations of DMAs were added
with the transfections. Two days after transfection, RLuc and FLuc
activities were measured using a dual-luciferase reporter assay. As
shown in Fig. 6A, addition of 10 M DMA-132 or DMA-135 reduced FLuc activity, which is under the control of SARS-CoV-2
5′-end and 3′-UTR, by approximately 50%. Addition of 10 M
DMA-155 resulted in the largest decrease in FLuc activity; specifically, FLuc signal was reduced by ~90%. A similar level of FLuc signal
reduction was achieved in the presence of 10-fold higher concentration of DMA-132 and DMA-135 when compared with DMA-155.
Activities of the control RLuc remained relatively constant for all
DMAs across all concentrations tested; this control indicates that
decreases in FLuc required SARS-CoV-2 sequence elements and
were not due to any putative cytotoxic effects of DMAs or to nonspecific effects on translation. To test whether the CoV-2 3′-UTR
contributes to DMA-mediated translational repression, we repeated
the experiment using a FLuc reporter, CoV-2–5′UTR–FLuc RNA,
in which the CoV-2 3′-UTR was replaced with vector-encoded sequence; thus, the CoV-2 5′-ends of both FLuc reporter RNAs are
the same (Fig. 6B). The effects of DMAs on translational repression
were virtually identical to those in Fig. 6A. We note that select
DMAs that inhibited SARS-CoV-2 5′-end–dependent FLuc translation (this work) had little effect on EV71 5′-UTR–dependent FLuc
translation (27). Thus, the DMAs act at the level of the SARS-CoV-2
5′-end and not at the level of putative structure present in the FLuc
coding region. Together, these results clearly demonstrate that
DMA-dependent suppression of SARS-CoV-2 luciferase reporter
activity requires only 5′-end sequences of the virus.
NMR profiling and in vitro affinity of 5′-SL-DMA interactions
Toward understanding potential mechanisms by which the DMAs
inhibit SARS-CoV-2 replication, we carried out single-point 13C-1H
TROSY HSQC (transverse relaxation-optimized spectroscopy–
heteronuclear single quantum coherence) titrations of DMA-132,
4 of 14
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Fig. 3. Conservation of 5′-end sequences encoding RNA structures in betacoronavirus genomes. Multiple sequence alignment showing percentage identity and
sequence coverage within the 5′-UTR and adjacent region of representative species within genus Betacoronavirus. (A) SL1–3. (B) SL 4–6. Viral subgenus is indicated as shown
in the key. Sequence numbering is standardized to the genome sequence start position of each taxon. Taxon labels show GenBank accession numbers and abbreviated virus names.
OC43, human coronavirus OC43; RousettusBat, Rousettus bat coronavirus; MERS, Middle East respiratory syndrome–related coronavirus; Bat-Hibeco, Bat Hp-betacoronavirus.

DMA-135, and DMA-155 into SL1 to SL6 of the 5′-region. We
selected this region of the 5′-UTR to NMR profile following the
reasoning that it contains SLs with assigned functions that can be
prepared at sizes amenable to facile NMR screening, shows a degree
Zafferani et al., Sci. Adv. 7, eabl6096 (2021)

26 November 2021

of selective pressure to maintain sequence and structure, and contains several noncanonical RNA elements that we hypothesize are
good targets for the DMAs. An advantage of using 13C-1H TROSY
HSQC titrations to profile small molecule–RNA interactions is
5 of 14
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Fig. 4. Chemical structure of the three lead molecules derived from the focused library screen against OC43-infected Vero E6 cell screening.

Fig. 5. Inhibition of SARS-CoV-2 infection by DMA leads without cellular toxicity. Vero E6 cells were infected with SARS-CoV-2 (MOI = 0.1) in the presence of
DMSO or the indicated compounds for 3 days followed by normalized measurement of virus titer in culture supernatant (black bars). Results were generated with
two independent experiments, each with two replicates. Cellular viability was assayed by measuring cellular ATP content in uninfected Vero E6 cells after 3 days of
treatment with the indicated compounds (gray bars).

that the extent of NMR signal perturbation provides a convenient
proxy on the degree of binding specificity, even in the absence of
chemical shift assignments. The designs of the individual SLs were
based on the reasoning that DMAs likely bind the 5′-region SLs at
noncanonical structural elements such as bulge, internal, or apical
loops. Therefore, we in vitro transcribed isolated SL domains using
13
C, 15N rNTPs (ribonucleoside triphosphate) that would maximize
NMR signal detection for the noncanonical elements over the base
paired regions (Fig. 7 and fig. S5). For example, SL1 was prepared
separately as A(13C, 15N) and C(13C, 15N) selectively labeled constructs because adenosines and cytosines are the most abundant
nucleobases within or proximal to its internal and apical loops, respectively. Using this strategy, we are able to efficiently profile each
5′-region SL to determine whether the DMAs bind with reasonable
affinity and specificity as determined by qualitative assessment of
the DMA-induced NMR signal perturbation. Figure 7 and fig. S5
summarize the effects that the addition of excess (5:1) DMAs has on
the NMR spectra of each major SL domain. First, we observed that
the DMAs induced differential chemical shift perturbations (CSPs)
or line broadening (LB) for each SL, and the largest signal perturbations (CSPs or LB) were observed in spectra recorded for SL1, SL4,
SL5a, and SL6 (Fig. 7). The assignments of SL1 and SL5a have been
Zafferani et al., Sci. Adv. 7, eabl6096 (2021)
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Fig. 6. Vero E6 cells were cotransfected with luciferase constructs and cultured
with various concentration of small molecule. (A) Vero E6 cells were cotransfected with
CoV-2-5’UTR-FLuc-3’UTR. (B) Vero E6 cells were cotransfected with Cov-2–5′UTR–FLuc
(left), and no change in inhibition was observed when compared to the presence
of 3′-UTR (right, DMA-135). Luciferase activity was measured 2 days later. Mean
values and SDs from three independent experiments are shown in the bar graphs.
***P < 0.001; **P < 0.01; N., not significant relative to the DMSO control, except for
the 5′UTR-FLuc-3′UTR comparison in (B), which is relative to DMA-135 at 0.1 M.

previously reported (35, 36). Each of these 5′ domains contains bulges
and/or other internal loops. Second, only a subset of the 13C-1H correlation peaks is perturbed in the spectra, providing initial evidence
that the DMAs interact through specific surfaces rather than delocalized binding. Third, the extent of the signal perturbations is also
differential between DMAs, with some DMAs inducing shifts of the
correlation peaks to new positions within the spectra of a given SL
and others inducing severe LB of the NMR signals. These variable
signal perturbations suggest that the DMAs interact with different
binding affinities and binding modes. None of the DMAs caused
substantial changes to spectra recorded on SL2, which contains a
5-nt CUUGU apical loop but no internal loops or bulges. Together,
the single-point 13C-1H TROSY HSQC titrations provide compelling evidence that the DMAs make specific interactions with the
SARS-CoV-2 5′-region via surfaces composed of noncanonical
structural elements.
6 of 14
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Fig. 7. Single-point 13C-1H TROSY HSQC titrations reveal that DMA-132, DMA-135, and DMA-155 bind with moderate affinity and specificity to SARS-CoV-2
5′-region SLs. The spectra were recorded at 900 MHz in 100% D2O buffer of 25 mM K2HPO4 and 50 mM KCl at pH 6.2. Temperatures (298, 303, or 308 K) were optimized
for each RNA construct to maximize the number of observed correlation peaks. The total RNA concentrations were set to 100 M while titrating fivefold excess DMA.
Zafferani et al., Sci. Adv. 7, eabl6096 (2021)
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Notably, SL1 and SL6 experienced the most substantial NMR signal perturbations upon addition of excess DMAs (Fig. 7). NMR
signal perturbations are observed at other SLs but to a lesser degree
based on our selection criteria. For SL1, addition of DMA-132 and
DMA-155 induced the migration of several correlation peaks to
new spectral positions (Fig. 7). By comparison, addition of DMA-135
induced severe LB of ~50% of the total observed correlation peaks
recorded for the A(13C, 15N) and C(13C, 15N) selectively labeled SL1
constructs (Fig. 7 and fig. S5). In the presence of fivefold excess
DMA-135, most of the nuclear Overhauser effect (NOE) stacking
patterns disappear for a CG(2H), AU(2H3′-5″) selectively labeled SL1
construct, whereas substantially more NOE cross-peaks are still
observed for the 5:1 (DMA-155)–SL1 complex (fig. S6). These differences likely reflect binding heterogeneity and collectively suggest
that DMA-132, DMA-135, and DMA-155 differentially interact with
SL1 despite having similar core scaffolds (Fig. 7).
For SL6, addition of excess DMA-155 induced a combination of
CSPs and LB to a greater extent than DMA-132 or DMA-135. To
further assess the nature of these signal perturbations on the SL6
structure, a 1H-1H NOE spectroscopy (NOESY; tm = 250 ms) spectrum was recorded with UG(2H), AC(2H3’-5″) selectively labeled SL6
constructs, which was chosen based on the abundance of A and C
residues in the bulge (Fig. 8A). Figure 8 shows the 1H-1H NOESY
spectra of free SL6 overlaid with its complex to which a 5:1 molar
ratio of DMA-155 was added. On the basis of the intra-NOEs observed between A and C residues of SL6, tentative chemical shift
assignments were determined (Fig. 8, B and C). The addition of
excess small molecule caused CSPs to A339H8, A339H2, A310H8,
A310H2, C311H6, and A314H8 spin systems, which are located
within or in proximity to the bulge. This supports a model in which
DMA-155 preferentially interacts with the bulge region of SL6.
Notably, the presence of intra-NOEs in the complex indicates the
preservation of base stacking within the (DMA-155)–SL6 complex.
In addition, the 1H-1H NOESY spectra of CUG(2H), A(2H3’-5″)
selectively labeled SL6 overlaid with its DMA-155–bound form
(Fig. 8C) show inter-NOEs between the methyl protons of DMA-155
[2.5 parts per million (ppm)] and both A339H2 (7.94 ppm) and
A310H2 (7.88 ppm), although these particular inter-NOEs are weak.
As further evidence of the involvement of A339 and A310 in binding, their H8 spin systems also showed CSPs upon the addition of
DMA-155. Four additional broad NOE peaks appeared between the
methyl protons and protons with chemical shifts between ~6.5 and
7 ppm (Fig. 8C). We reasoned that these might be intra-NOEs between the methyl groups and amino group located on the central
six-membered ring system. To further investigate the origin of these
NOEs, a 1H-1H NOESY spectrum of ACGU(2H)-labeled SL6 bound
to DMA-155 (shown in orange, Fig. 8C) displayed identical broad
NOE peaks. This shows that these peaks signify intra-NOEs within
DMA-155 itself, which do not appear in the 1H spectrum of the free
small molecule in D2O but only in the environment of the SL6 complex. The possibility of these peaks arising from inter-NOEs between
the amino of the RNA and methyl protons was eliminated on the basis
of 15N-HSQC NMR experiments of DMA-155 titrated into 15N fully
labeled SL6. In sum, through the support of intra- and inter-NOEs,
DMA-155 shows a degree of specificity to the bulge region of SL6.
Moreover, the affinity of the three leads for the SL constructs
was investigated via in vitro indicator displacement assays (IDAs)
(27, 37, 38). DMA-155 was revealed to be a strong binder with the
highest affinity for SL6, in agreement with NOE studies (Fig. 8 and
Zafferani et al., Sci. Adv. 7, eabl6096 (2021)
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fig. S17). DMA-135 showed weak affinity for SL1, SL4, and SL6; the
parent scaffold (DMA-001) and DMA-132 did not show binding
affinity against any of the constructs under these conditions. The
measured 50% competitive displacement dose (CD50) in vitro is about
10-fold weaker than the IC50 recorded via luciferase assays, which
may highlight the differences between these assays. CD50 measurements depend on both the affinity and binding mode of the indicator used, while in cell assays, these reflect binding in the presence of
a larger RNA context and in the presence of proteins. Additional biophysical studies are underway to better understand the relationship
between these in vitro and in cellulo assays.
In silico ligand screening of DMA-focused library against
5′-UTR and adjacent RNA structures
To generate potential three-dimensional (3D) models of each SL, we
used fragment assembly of RNA with full-atom refinement (FARFAR).
We chose FARFAR to generate preliminary models as it has consist
ently been demonstrated to be the most accurate RNA 3D prediction
algorithm (39, 40). We generated between 5000 and 100,000 models
for each SL and then generated ~15 representative clusters.
The lowest energy conformation from each cluster was used to
generate an ensemble for each SL that was submitted to ICM pocket
finder to find and characterize possible binding pockets (table S1).
Notably, SL2, which showed no change in 13C-1H HSQC NMR chemical shifts upon small-molecule addition, did not have any identifiable binding pocket. SL1, SL3, and SL5b presented binding pockets
with low to intermediate scores in terms of volume, area, hydrophobicity, buriedness, and druggability score (DLID) parameters often
used to describe a binding pocket’s fitness. Notably, SL3 and SL5b
presented minor CSPs upon small-molecule addition. 13C-1H TROSY
HSQC NMR experiments showed notable changes upon small-
molecule binding to SL1, SL5a, and SL6 (Fig. 7), all of which had the
highest scores in all parameters (Fig. 9). The structure that presents
the highest CSPs upon binding to the small-molecule leads, SL6,
is the only SL to have a binding pocket with positive DLID score
(0.45; table S1). DLID score has been found as a good predictor
of druggability of protein binding pockets but often presents highly
negative scores in RNA due to the charged backbone of RNA
(41, 42). Overall, this binding pocket analysis strongly correlates with
NMR experimental data.
We then docked our published 55-member DMA library against
the clustered FARFAR-generated SL structures (figs. S7 to S12). In
line with the results from the pocket analysis and NMR experimental
data, the overall number of hits across constructs is highest for SL1,
SL4, SL5a, and SL6, corroborating their potential as therapeutic targets.
Hit ligands DMA-132, DMA-135, and DMA-155 were among the
top predicted binding ligands. Furthermore, if the docked structures are limited to the sublibrary of DMAs tested against OC43 and
SARS-CoV-2, the three hit ligands score in the top 5 of every SL.
Notably, when analyzing the binding location that yielded the best
docking scores of the three hit molecules against SL6, we note that
while DMA-135 and DMA-155 bound best in one binding pocket
(Fig. 9F, blue), DMA-132 docks best in the adjacent binding pocket
(Fig. 9F, red). When comparing the NMR profiles of the three small
molecules, we note that DMA-135 and DMA-155 have a similar
perturbation pattern, while DMA-132 has a slightly different profile,
suggesting a possible different binding mode. To further investigate
this hypothesis, FARFAR 3D models were generated for every individual bulge and apical loop motif to increase the conformational
8 of 14
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Fig. 8. Detailed interaction of DMA-155 with SL6. (A) Representation of SL6 secondary structure and labeled nucleotides (red). (B) 1H-1H NOESY spectra (900 MHz,
tm = 250 ms) of free UG(2H), AC(2H3′-5″) selectively labeled SL6 (blue) and its DMA-155 complex (red), which were collected in 25 mM K2HPO4 and 50 mM KCl (pH 6.2) at
308 K in 100% D2O, show that DMA-155 has a degree of binding specificity. (C) 1H-1H NOESY spectra (900 MHz and tm = 250 ms) of free CUG(2H), A(2H3’-5″) selectively
labeled SL6 (red), its DMA-155 complex (black), and the fully deuterated RNA complexed with DMA-155 (orange) were collected in 25 mM K2HPO4 and 50 mM KCl (pH 6.2)
at 308 K in 100% D2O. On the secondary structure of SL6, the nucleotides highlighted in red represent the labeling scheme of the RNA.

diversity at these sites within the SL clusters, which are otherwise
largely dictated by the respective positions of the double stranded
regions. The DMA library was then rescreened against each of the
clustered motifs. The three small-molecule leads DMA-132, DMA-135,
and DMA-155 consistently scored among the top hits (figs. S8 to
S12). Furthermore, each of the molecules reported the best docking
score for SL1, SL5a, SL6, and, more specifically, for motifs created
for internal bulge motifs (figs. S13 to S15). In the case of DMA-135,
for example, the best docking score was found for the internal
Zafferani et al., Sci. Adv. 7, eabl6096 (2021)
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loop motif of SL1, in agreement with HSQC data that reported
DMA-135 as the best binder for SL1 (fig. S16). Analogously,
DMA-155 had the best docking score for the internal loop pocket of
SL6, in line with NOE data that identified DMA-155 as the best and
most specific binder for SL6 (fig. S17). While preliminary, this
docking analysis corroborates the NMR data and the fitness of these
ligands for SARS-CoV-2 5′-SL targeting while also supporting its
utility as a tool in the identification of new SARS-CoV-2 RNA-
targeting ligands.
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Fig. 9. Retrospective docking substantiates NMR findings. (A) Secondary structure representation of SL1 construct used in NMR studies. (B) SL1 3D model with
binding pockets highlighted in different colors identified via ICM pocket finder.
The model depicted is a representative conformer of the 15-confomer cluster generated for the internal loop motif. (C) conformation and binding pockets that yielded
the best docking scores of the three hit molecules DMA-132 (red), DMA-135 (green),
and DMA-155 (purple). (D) Secondary structure representation of SL6 construct used
in NMR studies. (E) SL6 3D model with binding pockets (red and blue) identified via
ICM pocket finder. Model depicted is a representative conformer of the 15-structure
clusters built for internal loop motif. (F) Conformer that yielded the best docking
scores for the three hit molecules, namely, DMA-132 (red), DMA-135 (green), and
DMA-155 (purple) represented in space-filling model.

DISCUSSION

Screening of synthetic RNA-focused libraries in recent years has
provided the field with many RNA binding bioactive small molecules
and some of the highest hit rates among small-molecule screening
approaches (43). Amiloride, a known RNA binding scaffold, has
been synthetically tuned for a range of RNA secondary structures
and recently yielded a novel antiviral lead for the treatment of
enterovirus 71. In this case, amiloride inhibited viral translation by
binding the viral 5′-UTR and modulating RNA:host protein interactions. SARS-CoV-2 also contains a highly conserved 5′-end that
is reported to play a crucial role in viral replication and hijacking of
host cell translational machinery. The presence of multiple bulge or
internal loops, the secondary structural elements that amilorides have
been reported to bind most effectively, makes the 5′-UTR and the
adjacent SL6 ideal therapeutically relevant targets for small-molecule
probing. An initial DMA-focused library screen against OC43-
infected Vero E6 cells allowed for the identification of three lead
compounds, namely, DMA-132, DMA-135, and DMA-155, that significantly reduced virus titer. Initial structure-activity relationships
could also be resolved, highlighting the critical substitution of
the dimethylamine group at the C5 position and rigid aromatic
Zafferani et al., Sci. Adv. 7, eabl6096 (2021)
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substituents at the C6 position. These molecules were also found to
be active against SARS-CoV-2 in both screening-format qRT-PCR
and infectious virus titer assays. Luciferase assays revealed the presence of the 5′-UTR and proximal region as necessary and sufficient
for translation inhibition upon small-molecule treatment. Markedly,
all in vitro assays identified DMA-155 as the strongest SARS-CoV-2
inhibitor, with the largest reduction in luciferase signal and highest
decrease in virus titer at 10 M.
NMR profiling of leads DMA-132, DMA-135, and DMA-155
against each of the major 5′-UTR and adjacent SL domains revealed
that the DMAs bind preferentially to SLs that contain large internal or
bulge loops. SL1’s NMR data revealed CSPs and LB with DMA-135,
which signifies its binding onto a specific surface with a disruption
in stacking interactions, unlike DMA-155. Notably, SL6, which contains a moderately conserved and weakly paired ~16-nt bulge loop,
showed one of the most notable CSPs when titrated with DMAs.
Specifically, NOE experiments revealed that DMA-155 binds specifically to SL6, a finding that was corroborated by in vitro IDAs,
which identified SL6 as the preferred target for DMA-155. The
5′-side of the SL6 bulge loop has been proposed to interact with
the SARS-CoV-2 nucleocapsid (N) protein under phase separation
conditions and may also affect genome packaging (44). We will
investigate the modulation of the N protein:SL6 interaction as a
potential antiviral mechanism in future work.
In silico analysis corroborated the experimental trend observed
with NMR experiments, identifying some of the SLs with predicted
bulges (SL1, SL4, SL5a, and SL6) as those with binding pockets with
highest druggability. The small molecules that showed the highest
antiviral activity, namely, DMA-132, DMA-135, and DMA-155,
scored highest in the SLs that reported substantial CSPs upon small-
molecule binding. In addition, refined docking of the three small-
molecule leads against motif-specific clusters revealed SL1 to be the
preferred target for DMA-135 and SL6 as the favored target for
DMA-155, in line with NMR and IDA results.
In summary, we here identified drug-like small molecules that
reduce SARS-CoV-2 replication and are the first antivirals to target
the conserved RNA SLs in the 5′-end region of SARS-CoV-2. Work
is underway to further characterize the mode of action of these
ligands, particularly putative impacts on RNA:protein interactions
and specific steps in the viral replication cycle. These leads are
uniquely poised to further elucidate the relationship between in vitro
preferential binding and small molecule–mediated SL-specific alterations of virus:host interactions. These small molecules offer the
opportunity to understand the contribution of individual 5′-end
SLs to viral proliferation in a system where mutational studies are
difficult because of genome size. Once characterized, we expect these
amiloride-based ligands to serve as chemical biology tools to help
understand CoV RNA molecular biology, such as N-dependent genome packaging and other cellular stages of the viral RNA replication process. We have established an efficient framework to identify
novel RNA-targeted CoV antivirals that will serve not only the
SARS-CoV-2 pandemic but future coronavirus pandemics.
MATERIALS AND METHODS

Analysis of sequence conservation
Representative betacoronavirus sequences were selected according
to official taxonomy as represented by the International Committee
for the Taxonomy of Viruses (45). Multiple sequence alignments of
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coronavirus sequences were constructed using BLAST and MAAFT
as implemented in GLUE (46–48). Alignments were manually inspected and adjusted using Se-Al. Position coverage and percentage
identity were calculated and visualized using JalView (49).
Cells and virus
Vero E6 (African green monkey kidney; ATCC CRL-1586) cells were
cultured in minimum essential medium (MEM) supplemented with
10% fetal bovine serum (FBS) (Thermo Fisher Scientific) and maintained at 33°C. Cells were infected with human coronavirus OC43
(ATCC VR-1558) at indicated MOI and incubated 1 hour at 33°C
for adsorption. Unbound virus was removed, and cells were refed
fresh medium with various concentrations of DMAs. Media from
infected cells were harvested 24 hours postinfection, and virus titers
were determined by plaque assay on Vero E6 cells. SARS-CoV-2
(USA-WA1/2020 strain; BEI Resources) was propagated and titered
on Vero E6 cells, with sequence confirmation of a P2 stock to confirm stability of the viral genome.
Effects of SARS-CoV-2 5′- and 3′-end sequence elements
on luciferase reporter activity
The reporter plasmid pCoV-2–5′UTR–FLuc–3′UTR contains the
SARS-CoV-2 5′-UTR and adjacent coding sequences in ORF1a
fused in-frame with the FLuc open reading frame, followed by the
SARS-CoV-2 3′UTR. For plasmid pCoV-2–5′UTR–FLuc, the Cov2 3′UTR was replaced with vector-encoded sequence. The plasmids
were provided by S.-R. Shih (Chang-Gung University, Taiwan).
Plasmid pRL, the Renilla luciferase control reporter vector, was purchased from Promega. CoV-2–5′UTR–FLuc–3′UTR, Cov-2–5′UTR–
FLuc, and RLuc RNAs were in vitro synthesized from these plasmid
templates using the MEGAscript T7 Transcription Kit (Thermo
Fisher Scientific).
Vero E6 cells were seeded in 24-well plates. Two hundred nanograms of reporter RNA, 5 l of SuperFect (Qiagen), and 400 l of
MEM with 10% FBS were combined and added to one well of cells.
Cells were incubated at 33°C for 4 hours, media were changed,
and various concentrations of DMAs were added. Two days after
transfection, IRES activity was determined by measuring RLuc and
FLuc activities using the Dual-Luciferase Reporter Assay System
(Promega).

specific to SARS-CoV-2 N gene and a standard curve derived from
in vitro synthesized RNA encoding N.
In addition, antiviral activity was tested against SARS-CoV-2
using a TCID50 assay, and Vero E6 cells were seeded at 1 × 105 per
well in a 24-well plate at 37°C for 24 hours. Cells and samples were
then transferred to a Biosafety Level 3 facility. Stocks of SARS-CoV-2
were diluted in Dulbecco’s modified Eagle’s medium (DMEM)/2%
FBS for a solution of 20,000 plaque-forming units (pfu)/ml. Growth
media was aspirated from 24-well plates and replaced with 495 l of
DMEM/2% FBS containing SARS-CoV-2 (20,000 pfu/ml) for an
MOI of 0.1. Five microliters of DMSO or compound was then immediately diluted into each well for final concentrations of 50 and
10 M. Plates were incubated at 37°C for 72 hours. Media were then
harvested, centrifuged at room temperature for 10 minutes at 1500g,
and then used for TCID50 assay. Serial dilutions of supernatant
from the treated cells were added to Vero E6 cells in 96-well plates,
and cells were monitored for cytopathic effect. Virus titer was
calculated from the numbers of positive wells using a modified
Reed and Muench method.

Cytotoxicity assays
Various concentrations of DMAs were added to Vero E6 cells in
culture. The cells were incubated at 33°C for 96 hours. Cell viability
was determined by MTT assay and measured at 570 nm according
to the manufacturer’s instructions (EMD Millipore). All experiments
were performed in triplicate. The concentration of DMAs required to
reduce cell viability to 50% of the control cells was expressed as CC50.

Synthesis and purification of RNA SL constructs
present at 5′-end
SL1 to SL6 of the 5′-end were in vitro transcribed using a standard
protocol from synthetic DNA templates from Integrated DNA
Technologies (Coralville, IA) (50, 51). The 3- to 6-ml reactions
involved the use of purified recombinant T7 RNA polymerase expressed in BL21 (DE3) cells. Depending on the labeling scheme
of each RNA, double-labeled, 13C and 15N, rNTPs and unlabeled
rNTPs were used in the reaction. Nucleotide labeling of the SLs was
based on the abundance of nucleotides in bulges and loops. The
labeling pattern for the 1H-13C HSQC experiments was as follows:
SL1 C(13C,15N)-labeled and A(13C,15N)-labeled, SL2 U(13C,15N)-
labeled, SL3 AU(13C,15N)-labeled, SL4 A(13C,15N)-labeled, SL5a
AU(13C,15N)-labeled, SL5b AU(13C,15N)-labeled, and SL6 AC(13C,15N)-
labeled. For the 1H-1H NOESY experiments, the labeling scheme
was SL6 UG(2H) AC(2H3′-5″), CUG(2H) A(2H3′-5″), and ACUG(2H)
selectively labeled constructs, along with a CG(2H), AU(2H3’-5″) selectively labeled SL1 construct.
Next, the SLs were purified on denaturing gels, ranging from 8 to
16%, and extracted using electroelution. After desalting with a
Millipore Amicon Ultra-4 centrifugal filter, the RNAs were annealed
by heating for 2 min at 95°C and flash cooled on ice. The samples
were thoroughly washed and concentrated down with a 100% D2O
buffer of 25 mM K2HPO4 and 50 mM KCl at pH 6.2. Using the
NanoDrop 2000 software (Thermo Fisher Scientific), the theoretical
extinction coefficients of the SLs were calculated to determine RNA
concentrations. Samples for NMR titrations contained 100 M RNA
in D2O buffer with a final volume of 200 l.

SARS-CoV-2 antiviral assays
Analysis of SARS-CoV-2 growth in cell culture supernatants was
performed using a simplified qRT-PCR assay as explained before
(34). Briefly, Vero E6 cells were infected with SARS-CoV-2 at an MOI
of 0.1 IU per cell in 96-well plates, and virus inoculum was removed
1 hour postadsorption and replaced with media containing serial
dilutions of the DMA compounds. Five microliters of cell culture
media containing released virions was collected at 24 hours
post infection and processed as detailed in previous studies (34).
Viral RNA levels were quantitated by qRT-PCR using primers

NMR profiling of DMA interactions with 5′-end structures
A 900-MHz spectrometer was used to record all NMR data. The
1
H-13C HSQC titrations were recorded with 100 M of selectively
labeled SL1 to SL6 in a 100% D2O buffer of 25 mM K2HPO4 and
50 mM KCl at pH 6.2 with a 200-l sample volume. Titrations of the
DMA molecules into the different SLs were collected at a molar ratio
of 5:1, DMA to RNA, at a temperature of either 298, or 303, or
308 K. For each construct, temperature optimization experiments
were done to determine the optimum temperature to conduct the
titrations with. Also, based on the optimized temperatures, 1H-1H
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NOESY spectra (tm = 250 ms) of selectively labeled SL6 samples and
their DMA-155 complexes were collected with a 200 M sample concentration in 25 mM K2HPO4, 50 mM KCl (pH 6.2) in 100% D2O at
a 200-l sample volume. At similar conditions, 1H-1H NOESY spectra
(tm = 250 ms) of selectively labeled SL1 were collected in the absence
and presence of DMA-135 and DMA-155 at a 5:1 molar ratio. The
NMR spectra were processed using NMRPipe/NMRDraw and
analyzed with NMRView J or Sparky (52–54).
Virtual ligand screening against SARS-CoV-2 5′-end
RNA structures
FARFAR model generation
FARFAR is part of the Rosetta 3 software package and can be obtained for free academic usage (https://www.rosettacommons.org/
software/license-and-download). Each SL was generated through the
following protocol.
rna_helix.py is a python wrapper for the Rosetta executable rna_
helix. rna_helix.py and is available in $ROSETTA/tools/rna_tools/bin,
where $ROSETTA is the Rosetta installation path. Below are the
commands to generate SL1.
rna_helix.py -seq gguu aacc -resnum 1–4 24–27 -o helix_1.pdb
rna_helix.py -seq acc ggu -resnum 8–10 17–19 -o helix_2.pdb
For each helix in an SL other than the nucleotides that flank
bulges and loops, we prebuild as idealized A-form helices with the
above commands. Modeling helical residues as idealized A-form
substantially reduce computational time, allowing for more models
to be built.
FARFAR modeling is performed through the rna_denovo executable
rna_denovo -nstruct 1000 -s helix_1.pdb helix_2.pdb -fasta input.
fasta -secstruct_file input.secstruct -minimize_rna true -out:file:silent
farfar.out
where -nstruct is the maximum number of models requested,
-fasta is the path of a fasta file containing the RNA sequence,
-secstruct is the path of a file (input.secstruct) containing the RNA
secondary structure in dot-bracket notation, -minimize_rna true
minimizes the RNA after fragment assembly, -s specifies the path
to the pdb files that contain static structures of our helices,
and -out:file:silent specifies the output file path to store all generated
models. Each SL was run on 100 cores for 24 hours; the number of
generated models is reported in table FARFAR (table S1).
To reduce the number of models to dock against, we performed
fixed-width clustering using the rna_cluster executable
rna_cluster -in:file:silent farfar.out -nstruct 15 -cluster:radius RADIUS
where -in:file:silent is a silent file of all models for a given
SL, -nstruct is the maximum number of clusters requested,
and -cluster:radius is max distance in heavy-atom root mean square
deviation between members of the same cluster.
Small-molecule docking
Virtual docking simulations were performed using ICM (55)
(Molsoft LLC. La Jolla, CA) using the SARS-CoV-2 5′-UTR structures obtained from FARFAR modeling and clustering. RNA structural elements’ binding pockets were defined using ICM Pocket
Finder module, and all the small-molecule protonation states were
adjusted to pH 7.0 using ChemAxon (www.chemaxon.com). RNA
ensembles were then combined into conformational stacks using
ICM’s “impose conformations.” Then, to create “flexible receptors”
to dock against that would reflect all of the conformations of
each structure, ICM’s “create 4D grid” function was used for each
Zafferani et al., Sci. Adv. 7, eabl6096 (2021)
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docking project. Each of the structures was then docked against a
library of 55 DMA molecules. The DMA library was saved in .sdf
file format, which was indexed for virtual ligand screening using
ICM-Pro. The virtual screening simulation was implemented with a
conformational search and optimization with a limit of 10 conformers
per molecule. The thoroughness was left at level 10.
Indicator displacement assay
A serial dilution of the seven SL RNAs (SL1, SL2, SL3, SL4, SL5a,
SL5b, and SL6) was performed in tris buffer (50 mM tris-HCl and
50 mM KCl, at pH 7.4) in a 96-well plate in triplicate. Eight microliters of each dilution was transferred to a 384-well plate followed by
8 l of a 500 nM solution of RiboGreen dye in the same buffer
(Invitrogen). The plates were excited at 487 nm (8-nm slit), and
emission was recorded at 525 nm (8 nm slit; focal height, 11.3 mm)
using a CLARIOstar plate reader (BMG labtech). The affinity of the
dye for the RNA construct was determined by fitting the raw fluorescence in GraphPad Prism version 8.3.1 for Macintosh [GraphPad
Software, La Jolla, California, USA (www.graphpad.com)] by fitting to
the [Agonist] versus response – variable slope model that uses Eq. 1
Top − Bottom
  
  
	
	
Y = Bottom + (X  HillSlope  ) * ──────────────
HillSlope
X 
  + EC  50 ^  HillSlope

(1)

where Y is normalized percent change in fluorescence intensity, X is
RNA concentration, Bottom is lowest fluorescence percent change, and
Top is highest fluorescence percent change. Affinity of the dye for
the RNA construct was used as the ideal RNA concentration for
small-molecule titrations.
The two most promising small-molecule leads (DMA-135 and
DMA-155) were then screened against SL1, SL4, SL5a, SL5b, and
SL6, but not against the short SL2 and SL3 for which the RiboGreen
dye showed weak affinity.
A serial dilution of DMA-135 and DMA-155 (0, 0.5, 1.0, 2.5, 5,
10.0, 12.5, 15, 20, 25, 40, 50, 75, 100, 225, 400, and 450 M) was
performed in phosphate buffer tris buffer (50 mM tris-HCl and
50 mM KCl, at pH 7.4) in a 96-well plate in triplicate. Eight microliters of each dilution was transferred to a 384-well plate, followed
by 8 l of a solution of SL RNA and 0.5 M RiboGreen (Invitrogen).
The 384-well plates were at 4000 rpm for 1 min and incubated in the
dark for 30 min. The plates were excited at 487 nm (8-nm slit), and
emission was read at 525 nm (8-nm slit; focal height, 11.3 nm) using
a CLARIOstar plate reader (BMG Labtech). Percent fluorescence
indicator displacement (%FID) was calculated by subtracting and,
subsequently, dividing by the blank wells with RNA-dye complex and
no small molecule as shown in Eq. 2
F    − F
  0  )  * 100	
	%FID = (─
F 0

(2)

where F0 is the fluorescence of the blank well with RNA + dye and
no small molecule, and F is the fluorescence of the well with all three
components (RNA + dye + small molecule).
Each technical triplicate was averaged, and the resulting FID values
were averaged between three independent experiments. The binding
curve and median effective concentration (EC50) value were obtained
by using a nonlinear fit curve agonist versus response with variable
slope at four parameters [GraphPad Prism Software version for
Macintosh 8.3.1, La Jolla, California, USA (www.graphpadprism.com)]
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as shown in Eq. 1. Reported values are averages of three independent
experiments ± SD.
SUPPLEMENTARY MATERIALS

Supplementary material for this article is available at https://science.org/doi/10.1126/
sciadv.abl6096
View/request a protocol for this paper from Bio-protocol.
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